Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ATRAthis companyAtara Biotherapeutics, Inc.	$8.18	6.93×	-5.89×	1.88×	7.02×	-5049.6%	82.4%	29.7%	27.1%	-84.9%	222.7%	-22.4%	-1.37×	1.15×	9.46×	0.82×	0.0%	1	-135.86	2	C
CLNNClene Inc.	$4.41	-2.22×	-3.29×	289.36×	-3.38×	-148.3%	78.5%	-11541.5%	-13086.5%	148.8%	-188.6%	-32.1%	-1.23×	-0.75×	-8.61×	0.83×	0.0%	2	-23.05	2	C
CNTXContext Therapeutics Inc.	$0.19	-3.87×	2.31×	0×	-2.05×	231.0%	0.0%	0.0%	0.0%	-59.7%	-65.5%	-18.9%	0×	1.82×	0×	8.52×	0.0%	2	-5.58	3	B
COYACoya Therapeutics, Inc.	$3.12	-4.57×	2.26×	12.21×	-2.37×	45.7%	99.7%	-255.0%	-267.1%	-49.3%	-46.0%	-11.1%	0×	2.21×	0×	8.5×	0.0%	3	8.76	1	D+
CSBRChampions Oncology, Inc.	$4.87	-74.5×	20.93×	1.39×	183.22×	-13.9%	48.0%	-1.9%	-2.0%	-29.8%	-13.3%	-6.1%	1.15×	-0.8×	0×	0.96×	0.0%	3	-0.28	1	D+
MGNXMacroGenics, Inc.	$2.47	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
Peer median	—	-3.87×	2.26×	1.39×	-2.37×	-13.9%	71.1%	-48.7%	-49.9%	-49.3%	-46.0%	-18.9%	0×	-0.75×	0×	5.1×	0.0%	2	-4.43	1	—